Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a
subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:
TEVA) and Jiangsu Nhwa Pharmaceutical Co., Ltd (“Nhwa”) today
announced it formed a partnership for the marketing and
distribution of Teva’s AUSTEDO (deutetrabenazine) for the treatment
of neurodegenerative and movement disorders - chorea associated
with Huntington’s disease (HD) and tardive dyskinesia (TD) in
adults. The partnership intends to increase patients’ access to
Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s
neuro-psychiatric health sector.
“Nhwa has deep neuro-psychiatry expertise and capabilities, from
research and development to commercialization,” commented Theodor
Wee, General Manager of Teva Greater China. “Together, we can
promote cost-effective delivery of safe, quality medicines and
contribute to the sustainability of China’s healthcare system.”
Huntington’s disease is a rare and fatal neurodegenerative
disorder. Chorea, one of the most striking physical manifestations
of Huntington’s disease, is a neurological disorder that causes
involuntary, random muscle movements. It is one of the main
symptoms of the disease, occurring in up to 90% of adults living
with Huntington’s disease1.
Tardive dyskinesia is another disorder that results in
repetitive and uncontrollable movements of the tongue, lips, face,
trunk and extremities, affecting 20-50% of patients on long-term
antipsychotic medication. For patients with schizophrenia, who are
more likely to be treated with antipsychotic medication, the
prevalence of TD in China is higher (36.0%~46.5% [234]), than the
global average (25.3%5)..
“As the first deuterated drug approved in China, AUSTEDO offers
an innovative treatment for chorea associated with Huntington’s
disease and tardive dyskinesia in adults—debilitating disorders
that directly impact daily function and quality of life,” added Sun
Jiaquan, President and CEO of Nhwa.
In a deuterated drug, hydrogen atoms are replaced with
deuterium, which may significantly lower metabolism rates. The
deuterium technology used in AUSTEDO allows less frequent dosing
for patients.
“We are committed to addressing the pressing needs of patients
in China with more innovative medicines, in line with our
commitment throughout our International Markets region and across
the globe,” said Mark Sabag, EVP and Head of International Markets
at Teva. “This partnership assists us with further growing AUSTEDO
as a global leading brand, with over $1.2 billion in revenues in
2023, and to deliver on Teva’s Pivot to Growth strategy and
providing better health for our patients.”
About AUSTEDO
AUSTEDO is the first and only vesicular monoamine transporter 2
(VMAT2) inhibitor approved by the U.S. Food and Drug Administration
in adults for the treatment of tardive dyskinesia (TD) and for the
treatment of chorea associated with Huntington’s disease (HD).
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
global pharmaceutical leader with a category-defying portfolio,
harnessing our generics expertise and stepping up innovation to
continue the momentum behind the discovery, delivery, and expanded
development of modern medicine. For over 120 years, Teva's
commitment to bettering health has never wavered. Today, the
company’s global network of capabilities enables its ~37,000
employees across 58 markets to push the boundaries of scientific
innovation and deliver quality medicines to help improve health
outcomes of millions of patients every day. To learn more about how
Teva is all in for better health, visit www.tevapharm.com.
About Jiangsu Nhwa Pharmaceutical
Jiangsu Nhwa Pharmaceutical Co., Ltd., founded in 1978, is a
leading CNS company in China. Over the past 40 years, Nhwa is
exclusively dedicated to developing innovative and differentiated
pipeline in the areas of anesthesia, analgesia, psychiatry and
neurology via in-house R&D and global partnership.
As a fully integrated pharmaceutical company with more than 4000
employees, Nhwa has comprehensive capabilities in research,
clinical development, manufacturing and commercialization of CNS
drugs. In recent years, Nhwa has further strengthened its
leadership in CNS field in China by providing the services of
precision diagnosis of CNS disorders (Shanghai N-yuen Biotechnology
Company), and investing the largest Chinese CNS internet health
platform (Happy Mood).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to: our ability to successfully
commercialize AUSTEDO in China and globally; our strategic
partnership with Jiangsu Nhwa; our ability to successfully compete
in the marketplace including our ability to develop and
commercialize additional pharmaceutical products; our ability to
successfully execute our Pivot to Growth strategy, including to
expand our innovative and biosimilar medicines pipeline and
profitably commercialize the innovative medicines and biosimilar
portfolio, whether organically or through business development, and
to sustain and focus our portfolio of generics medicines; and other
factors discussed in this press release, and in our Annual Report
on Form 10-K for the year ended December 31, 2023, including in the
sections captioned "Risk Factors” and “Forward Looking Statements.”
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
1 Haddad MS, Cummings JL. Psychiatr Clin North Am
1997;20:791–807
2 Hui L, et al. Schizophr Res. 2017 Apr;182:104-109.
3 Uludag K, et al. Asian J Psychiatr. 2021 Dec;66:102877.
4 Liang Q, et al. J Psychiatr Res. 2022 Jul;151:181-187.
5 Carbon M, et al. J Clin Psychiatry. 2017
Mar;78(3):e264-e278
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240226932316/en/
IR Ran Meir, +1 (267) 468-4475 Yael Ashman, +972 (3) 914 8262
Sanjeev Sharma, +1 (973) 658 2700 PR Kelley Dougherty, +1 (973)
832-2810 Eden Klein, +972 (3) 906 2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024